tiprankstipranks
Advertisement
Advertisement

NGNE Stock Latest News

Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
RatingsBuy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
2d ago
NGNE
Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
PremiumRatings
Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
4d ago
NGNE
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
PremiumCompany Announcements
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
4d ago
NGNE
1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
PremiumMarket News
1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
4d ago
NGNE
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
PremiumThe Fly
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
4d ago
EL
RL
Neurogene reports FY25 EPS ($4.24) vs ($4.28) last year
PremiumThe FlyNeurogene reports FY25 EPS ($4.24) vs ($4.28) last year
4d ago
NGNE
NGNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
NGNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7d ago
NGNE
Block upgraded, Duolingo downgraded: Wall Street’s top analyst calls
Premium
The Fly
Block upgraded, Duolingo downgraded: Wall Street’s top analyst calls
29d ago
HON
LUV
Canaccord starts Neurogene with Buy rating, $200 price target
PremiumThe Fly
Canaccord starts Neurogene with Buy rating, $200 price target
29d ago
NGNE
Neurogene initiated with a Buy at Canaccord
PremiumThe Fly
Neurogene initiated with a Buy at Canaccord
29d ago
NGNE
Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares
PremiumThe Fly
Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares
29d ago
NGNE
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy
PremiumCompany Announcements
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy
30d ago
8K
NGNE
Neurogene announces Treakthrough Therapy Designation for NGN-401
PremiumThe FlyNeurogene announces Treakthrough Therapy Designation for NGN-401
30d ago
NGNE
Neurogene initiated with an Outperform at LifeSci Capital
Premium
The Fly
Neurogene initiated with an Outperform at LifeSci Capital
2M ago
NGNE
Neurogene outlines 2026 milestones for NGN-401 Rett therapy
Premium
Company Announcements
Neurogene outlines 2026 milestones for NGN-401 Rett therapy
3M ago
8K
NGNE
Short Report: Vera Therapeutics bears retreat as stock rallies
PremiumThe Fly
Short Report: Vera Therapeutics bears retreat as stock rallies
3M ago
MBLY
MDGL
Neurogene Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Neurogene Inc. Reports Q3 2025 Financial Results
4M ago
NGNE
Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating
PremiumRatings
Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating
4M ago
NGNE
Promising Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment: Analyst Recommends ‘Buy’
PremiumRatings
Promising Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment: Analyst Recommends ‘Buy’
4M ago
NGNE
Positive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program
PremiumRatingsPositive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program
4M ago
NGNE
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
Premium
Company Announcements
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
4M ago
NGNE
Neurogene reports Q3 EPS (99c) vs. ($1.19) last year
Premium
The Fly
Neurogene reports Q3 EPS (99c) vs. ($1.19) last year
4M ago
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >